After 17 and a half years with metastatic primary peritoneal cancer, a former hospital executive explains how an AI health agent helped her after discharge.
|Articles|April 19, 2021
Cancer Survivors and Patients Share Their Experience With Seeking Second Opinions on Their Diagnosis and Treatment
Author(s)Ryan McDonald
On social media, CURE® recently asked its readers to share if they sought a second opinion when discussing their cancer diagnosis and treatment. Here’s what some of them said.
Advertisement
- “Yes. My first oncologist had me on watch-and-wait at stage 4. I got a new oncologist who started me on chemotherapy and now I am in remission.” – B.S.
- “Yes. Both oncology surgeons said the same thing. I was very lucky.” – D.Z.
- “Yes, I did to validate the chemotherapy recommendation and approach.” – C.M.
- “No, I had complete trust in the team of doctors recommended by my primary doctor.” – L.R.
- “Yes. I saw three oncologists. They gave me two years to live. Five years later, and I am still here. Fat and healthy, thanks to radical radiation.” – L.V.Z.
- “I am about to get a second opinion for my third cancer. More info can only empower me as a patient, to know I have the best team and plan aligning with my goals.” – J.V.
- “Yes, and I switched my surgery to my second opinion doctor. There’s been no evidence of disease for six years.” – M.C.
- “Yes. I was stage 2a and they recommended that I seek out other opinions! It was a group effort!” – L.L.
- “My doctor strongly recommended that I seek a second opinion before deciding on my cancer treatment. I did tons of research, read dozens of books, spoke with many friends, family and others with cancer. But I didn't take my doctor's advice to seek a second opinion from another doctor. Even though my treatment was very successful, I'm not happy that I didn't follow the doctor's advice. If my treatment failed, I would have not only regretted my decision but kicked myself for not taking the time to seek a second opinion. If I had followed the doctor's advice, then if my treatment of choice failed, at least I could take comfort in knowing that I did my homework.” – G.G.
- “Yes, I had a rare cancer diagnosis, so my doctor encouraged me to seek another opinion. Felt better going through treatment knowing both doctors agreed with diagnosis.” – L.R.
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
Sue Weldon, a 22-year breast cancer survivor and Unite for HER founder, explains how integrative therapies helped her heal after chemotherapy.
Relatives of people with BRCA1 or BRCA2 variants completed genetic testing more often when a navigator reached out directly than when they received a letter.
The FDA approval is based on the phase 3 BRUIN CLL-313 trial, in which 94% of patients responded to Jaypirca compared with 81% who received chemoimmunotherapy.
Giredestrant plus Afinitor lowered the risk of cancer worsening or death by 62% in patients with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer.
Five-year results presented at ASTRO 2026 show a five-week radiation schedule after prostatectomy controls cancer as well as a seven-week course. But serious urinary side effects were more common.
A study of more than 17,000 patients ages 23 to 64, presented at ASTRO 2026, found that only about 28% took endocrine therapy consistently for five years, and people who skipped radiation were more likely to fall off. Here's what to weigh before making that choice.
September brought new options for breast, lung, kidney, bile duct, skin and neuroendocrine cancers, plus a brain tumor scan and easier lung cancer treatment.
Advertisement
Advertisement
Trending on CURE
1
Radiation Oncologist Answers Top Questions About Radiation Therapy
2
5 Years of Breast Cancer Advances: A Timeline of FDA Approvals and What They Mean for Patients
3
FDA Approves Jaypirca as First-Line Treatment for CLL and SLL
4
Giredestrant Combo Cuts Progression Risk by 44% in Advanced Breast Cancer
5